Rowlandmiller & PARTNERS.ADV Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Rowlandmiller & PARTNERS.ADV lifted its position in Pfizer Inc. (NYSE:PFE) by 1.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 84,109 shares of the biopharmaceutical company’s stock after purchasing an additional 902 shares during the quarter. Rowlandmiller & PARTNERS.ADV’s holdings in Pfizer were worth $2,434,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of PFE. Marshall Wace LLP boosted its stake in shares of Pfizer by 279.3% in the second quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock valued at $150,481,000 after purchasing an additional 8,378,173 shares during the period. Swedbank AB purchased a new position in shares of Pfizer in the first quarter valued at approximately $172,902,000. International Assets Investment Management LLC purchased a new position in shares of Pfizer in the third quarter valued at approximately $146,481,000. Pzena Investment Management LLC boosted its stake in shares of Pfizer by 181.6% in the first quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock valued at $212,855,000 after purchasing an additional 4,947,000 shares during the period. Finally, Van ECK Associates Corp raised its holdings in Pfizer by 21.8% in the first quarter. Van ECK Associates Corp now owns 15,813,328 shares of the biopharmaceutical company’s stock valued at $438,820,000 after acquiring an additional 2,829,178 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $28.65 on Friday. The firm has a market capitalization of $162.35 billion, a P/E ratio of -62.28, a PEG ratio of 1.01 and a beta of 0.67. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54. The company’s fifty day moving average is $29.07 and its two-hundred day moving average is $28.48. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.67 EPS. Analysts forecast that Pfizer Inc. will post 2.67 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 5.86%. Pfizer’s dividend payout ratio is currently -365.21%.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Barclays raised their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. UBS Group raised their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Finally, Wells Fargo & Company raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.91.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.